J9345 Retifanlimab-dlwr - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Retifanlimab-dlwr

Brand Name:

Zynyz

Strength:

1mg

HCPCS:

J9345

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-1

Oral (Y/N):

No

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

Aug. 28, 2023

CMS Discontinuation Date:

Status:

In Use